Ridgefield Acquisition is a dormant shell company with no operations, no revenue, and no employees other than its Chairman and CEO, Steven Bronson, who takes no salary. Ridgefield suspended all operations in July 2000 following a series of failed or divested businesses, including an early depaneling and routing business sold in 1999 and an abandoned micro-robotic device development effort. Ridgefield holds a patent for an automated chromosome microdissection system through its wholly-owned subsidiary, Bio-Medical Automation, but has never generated revenue from it. Today, Ridgefield's sole activity is filing required SEC reports and searching for a merger, acquisition, or business combination with a viable operating company. Ridgefield's appeal to potential targets is its existing public company status, which can give an acquisition target public market access and liquidity without a traditional IPO — a so-called reverse merger vehicle. Ridgefield acknowledges that its limited capital may force it to pursue less attractive acquisition targets than better-funded competitors.